The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
Open accessAbstract
Small interfering RNA (siRNA) molecules are potent effectors of post-transcriptional gene silencing. Using noninvasive bioluminescent imaging and a mathematical model of siRNA delivery and function, the effects of target-specific and treatment-specific parameters on siRNA-mediated gene silencing are monitored in cells stably expressing the firefly luciferase protein. In vitro, luciferase protein levels recover to pre-treatment values within <1 week in rapidly dividing cell lines, but take longer than 3 weeks to return to steady-state levels in nondividing fibroblasts. Similar results are observed in vivo, with knockdown lasting approximately 10 days in subcutaneous tumors in A/J mice and 3-4 weeks in the nondividing hepatocytes of BALB/c mice. These data indicate that dilution due to cell division, and not intracellular siRNA half-life, governs the duration of gene silencing under these conditions. To demonstrate the practical use of the model in treatment design, model calculations are used to predict the dosing schedule required to maintain persistent silencing of target proteins with different half-lives in rapidly dividing or nondividing cells. The approach of bioluminescent imaging combined with mathematical modeling provides useful insights into siRNA function and may help expedite the translation of siRNA into clinically relevant therapeutics for disease treatment and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“Since its discovery in Caenorhabditis elegans in 1998 ( 1 ), it has rapidly attracted attention from researchers in fields ranging from genetics to clinical medicine.”
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Unlocking the potential of the human genome with RNA interference
Hannon, G. J., & Rossi, J. J. (2004) · Nature · doi:10.1038/nature02870 · Cited by 1,064
siRNAs: applications in functional genomics and potential as therapeutics
Dorsett, Y., & Tuschl, T. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1345 · Cited by 909
siRNA function in RNAi: A chemical modification analysis
CHIU, Y.-L., & RANA, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 860
Analysis of human transcriptomes
Velculescu, V. E., Madden, S. L., Zhang, L., Lash, A. E., Yu, J., Rago, C., Lal, A., Wang, C. J., Beaudry, G. A., Ciriello, K. M., et al. (1999) · Nature Genetics · doi:10.1038/70487 · Cited by 774
siRNA-directed inhibition of HIV-1 infection
Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J., Lee, S.-K., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002) · Nature Medicine · doi:10.1038/nm725 · Cited by 773
In vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Self-citationLocked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
Elm n, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki193 · Cited by 559
Kinetic analysis of the RNAi enzyme complex
Haley, B., & Zamore, P. D. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb780 · Cited by 544
Tiscornia, G., Singer, O., Ikawa, M., & Verma, I. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437912100 · Cited by 540
Methods of Blood Collection in the Mouse
Hoff, J. (2000) · Cited by 515
Approaches for the sequence-specific knockdown of mRNA
Scherer, L. J., & Rossi, J. J. (2003) · Nature Biotechnology · doi:10.1038/nbt915 · Cited by 455
RISC is a 5′ phosphomonoester-producing RNA endonuclease
Martinez, J., & Tuschl, T. (2004) · Genes & Development · doi:10.1101/gad.1187904 · Cited by 407
Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo
Bertrand, J.-R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., & Malvy, C. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02013-2 · Cited by 400
Expanding small RNA interference
Tuschl, T. (2002) · Nature Biotechnology · doi:10.1038/nbt0502-446 · Cited by 395
Visualizing the kinetics of tumor-cell clearance in living animals
Sweeney, T. J., Mailänder, V., Tucker, A. A., Olomu, A. B., Zhang, W., Cao, Y.-A., Negrin, R. S., & Contag, C. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12044 · Cited by 350
Godfrey, T. E., Kim, S.-H., Chavira, M., Ruff, D. W., Warren, R. S., Gray, J. W., & Jensen, R. H. (2000) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60621-6 · Cited by 321
siRNA therapeutics: big potential from small RNAs
Ryther, R. C. C., Flynt, A. S., Phillips, J. A., & Patton, J. G. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302356 · Cited by 301
Improving the efficiency of RNA interference in mammals
Mittal, V. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1323 · Cited by 286
Song, E., Lee, S.-K., Dykxhoorn, D. M., Novina, C., Zhang, D., Crawford, K., Cerny, J., Sharp, P. A., Lieberman, J., Manjunath, N., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7174-7181.2003 · Cited by 230
Development of a Nonviral Gene Delivery Vehicle for Systemic Application
Pun, S. H., & Davis, M. E. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0155768 · Cited by 223
Challita, P. M., Skelton, D., el-Khoueiry, A., Yu, X. J., Weinberg, K., & Kohn, D. B. (1995) · Journal of Virology · doi:10.1128/jvi.69.2.748-755.1995 · Cited by 209
Varga, C. M., Tedford, N. C., Thomas, M., Klibanov, A. M., Griffith, L. G., & Lauffenburger, D. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302495 · Cited by 185
Ignowski, J. M., & Schaffer, D. V. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20059 · Cited by 164
Rajvanshi, P., Kerr, A. S., Bhargava, K. K., Burk, R. D., & Gupta, S. K. (1996) · Hepatology · doi:10.1002/hep.510230313 · Cited by 152
Target accessibility dictates the potency of human RISC
Brown, K. M., Chu, C., & Rana, T. M. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb931 · Cited by 149
Davis, M. E., Pun, S., Bellocq, N. C., Reineke, T. M., Popielarski, S. R., Mishra, S., & Heidel, J. D. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043456179 · Cited by 145
Quantitative Analysis of Synthetic Gene Delivery Vector Design Properties
Varga, C. M., Hong, K., & Lauffenburger, D. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0475 · Cited by 120
Kobayashi, N., Nishikawa, M., Hirata, K., & Takakura, Y. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.541 · Cited by 118
Long‐lasting RNAi activity in mammalian neurons
Omi, K., Tokunaga, K., & Hohjoh, H. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00017-1 · Cited by 97
Krol, A., Maresca, J., Dewhirst, M. W., & Yuan, F. (1999) · PubMed · Cited by 97
On the delivery of small interfering RNAs into mammalian cells
Sioud, M. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.4.639 · Cited by 92
Transplantation of endothelial cells corrects the phenotype in hemophilia A mice
Kumaran, V., Benten, D., Follenzi, A., Joseph, B., SARKAR, R., & Gupta, S. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01508.x · Cited by 84
Short Interfering RNA (siRNA)—Mediated RNA Interference (RNAi) in Human Cells
Caplen, N. J., & Mousses, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.007 · Cited by 84
Andrianaivo, F., Lecocq, M., Coninck, S. W., Wattiaux, R., & Jadot, M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.574 · Cited by 74
Keeping health and safety first.
Hicks, J. M. (2000) · PubMed · doi:10.1038/5000058 · Cited by 66
Bergstrom, C. T., McKittrick, E., & Antia, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1931639100 · Cited by 65
Overhoff, M. G., Wünsche, W., & Sczakiel, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh168 · Cited by 60
Pathak, A. P., Artemov, D., Ward, B. D., Jackson, D. G., Neeman, M., & Bhujwalla, Z. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3682 · Cited by 59
Schibler, U. (2003) · Science · doi:10.1126/science.1090810 · Cited by 57
Dynamics of gene silencing by RNA interference
Raab, R. M., & Stephanopoulos, G. N. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20216 · Cited by 55
The RNA Silencing Pathway: The Bits and Pieces That Matter
Groenenboom, M., Marée, A. F. M., & Hogeweg, P. (2005) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0010021 · Cited by 55
Lingor, P., Michel, U., Schöll, U., Bähr, M., & Kügler, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.170 · Cited by 53
Optimizing RNA interference for application in mammalian cells
Medema, R. H. (2004) · Biochemical Journal · doi:10.1042/bj20040260 · Cited by 52
Molecular and Cellular Barriers Limiting the Effectiveness of Antisense Oligonucleotides
Roth, C. M. (2005) · Biophysical Journal · doi:10.1529/biophysj.104.054080 · Cited by 31
Cited by
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
“With siRNA, the gene inhibition kinetics are greatly influenced by cell-cycle time”
BackgroundGoh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Metadata
- Authors
- Bartlett, D. W.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-01-08
- Volume
- 34
- Issue
- 1
- Pages
- 322-333
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2103802203
- Cited by
- 592
- References
- 49
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.